Table S1.
Survival of primary lung cancer of all 174 patients diagnosed at University Hospital of North Norway 2008–2010
| ID | Sex | Age-group, years | COPD diagnosis | Emph | PaO2, range | PaCO2, range | Cancer | Stage | Time | D |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 30–74 | No COPD | 0 | 10–15 | 3–4.9 | Ad-NSCLC | III | 377 | 1 |
| 2 | M | 30–74 | Missing – spirometry | 0 | NA | NA | SCC – NSCLC | IV | 340 | 1 |
| 3 | M | 30–74 | No COPD | 1 | 10–15 | 3–4.9 | SCLC | IV | 157 | 1 |
| 4 | M | 30–74 | No COPD | 0 | 10–15 | 3–4.9 | SCLC | IV | 547 | 1 |
| 5 | M | 30–74 | No COPD | 0 | 10–15 | 5–5.9 | Ad-NSCLC | IV | 2,067 | 1 |
| 6 | M | 30–74 | No COPD | 0 | 10–15 | 5–5.9 | SCC – NSCLC | III | 1,243 | 1 |
| 7 | M | 30–74 | No COPD | 0 | 10–15 | 3–4.9 | SCC – NSCLC | III | 279 | 1 |
| 8 | M | 30–74 | Known COPD | 1 | 4–8.4 | 5–5.9 | SCLC | III | 365 | 1 |
| 9 | F | 75–91 | Known COPD | 0 | 10–15 | 5–5.9 | SCLC | III | 620 | 1 |
| 10 | M | 75–91 | Known COPD | 0 | 8.5–9.9 | 3–4.9 | SCLC | IV | 16 | 1 |
| 11 | F | 30–74 | No COPD | 0 | 10–15 | 3–4.9 | Other – NSCLC | I | 803 | 1 |
| 12 | M | 75–91 | No COPD | 1 | 4–8.4 | 5–5.9 | SCLC | IV | 77 | 1 |
| 13 | F | 30–74 | No COPD | 0 | 10–15 | 5–5.9 | Ad-NSCLC | I | 353 | 1 |
| 14 | M | 30–74 | No COPD | 1 | 10–15 | 3–4.9 | SCLC | IV | 188 | 1 |
| 15 | M | 30–74 | No COPD | 0 | 10–15 | 5–5.9 | SCC – NSCLC | II | 289 | 1 |
| 16 | F | 30–74 | No COPD | 1 | 4–8.4 | 6–10 | SCC – NSCLC | III | 2,175 | 1 |
| 17 | M | 30–74 | Missing – spirometry | 0 | 10–15 | 5–5.9 | SCC – NSCLC | IV | 104 | 1 |
| 18 | M | 75–91 | Missing – spirometry | 1 | 4–8.4 | 3–4.9 | NA | IV | 10 | 1 |
| 19 | M | 30–74 | No COPD | 0 | 10–15 | 3–4.9 | Other – NSCLC | IV | 41 | 1 |
| 20 | M | 30–74 | No COPD | 0 | 10–15 | 3–4.9 | SCLC | NA | 155 | 1 |
| 21 | F | 30–74 | No COPD | 0 | 8.5–9.9 | 5–5.9 | Ad-NSCLC | IV | 245 | 1 |
| 22 | M | 30–74 | No COPD | 0 | 10–15 | 5–5.9 | SCC – NSCLC | IV | 116 | 1 |
| 23 | F | 30–74 | No COPD | 1 | 10–15 | 3–4.9 | Ad-NSCLC | IV | 131 | 1 |
| 24 | M | 30–74 | Known COPD | 1 | 4–8.4 | 3–4.9 | Ad-NSCLC | IV | 287 | 1 |
| 25 | M | 75–91 | No COPD | 1 | 10–15 | 5–5.9 | SCC – NSCLC | IV | 45 | 1 |
| 26 | F | 30–74 | No COPD | 0 | 10–15 | 3–4.9 | Ad-NSCLC | III | 1,787 | 1 |
| 27 | M | 75–91 | Undiagnosed COPD | 1 | 8.5–9.9 | 5–5.9 | SCC – NSCLC | IV | 52 | 1 |
| 28 | F | 30–74 | Missing – spirometry | 1 | 4–8.4 | 5–5.9 | SCC – NSCLC | IV | 54 | 1 |
| 29 | M | 30–74 | No COPD | 0 | 10–15 | 3–4.9 | NA | IV | 162 | 1 |
| 30 | M | 75–91 | Known COPD | 1 | 4–8.4 | 6–10 | SCC – NSCLC | IV | 319 | 1 |
| 31 | F | 30–74 | No COPD | 0 | 10–15 | 3–4.9 | Ad-NSCLC | IV | 561 | 1 |
| 32 | M | 30–74 | Known COPD | 1 | 4–8.4 | 5–5.9 | SCLC | IV | 1,076 | 1 |
| 33 | M | 30–74 | Missing – spirometry | 1 | NA | NA | SCC – NSCLC | III | 91 | 1 |
| 34 | M | 75–91 | Known COPD | 0 | 10–15 | 5–5.9 | SCLC | III | 27 | 1 |
| 35 | M | 75–91 | No COPD | 0 | 10–15 | 3–4.9 | SCLC | IV | 7 | 1 |
| 36 | F | 30–74 | No COPD | 0 | 4–8.4 | 5–5.9 | Ad-NSCLC | IV | 76 | 1 |
| 37 | F | 75–91 | No COPD | 0 | 10–15 | 3–4.9 | Ad-NSCLC | II | 192 | 1 |
| 38 | F | 75–91 | No COPD | 1 | 10–15 | 3–4.9 | SCC – NSCLC | II | 370 | 1 |
| 39 | F | 30–74 | No COPD | 1 | 8.5–9.9 | 6–10 | Ad-NSCLC | I | 377 | 1 |
| 40 | M | 75–91 | Missing – spirometry | 0 | 10–15 | 5–5.9 | SCC – NSCLC | IV | 36 | 1 |
| 41 | F | 30–74 | Known COPD | 0 | 10–15 | 5–5.9 | Other – NSCLC | III | 33 | 1 |
| 42 | M | 30–74 | Known COPD | 0 | 4–8.4 | 5–5.9 | SCLC | III | 1,461 | 1 |
| 43 | M | 30–74 | No COPD | 1 | 10–15 | 3–4.9 | Other – NSCLC | IV | 141 | 1 |
| 44 | F | 30–74 | Missing – spirometry | 1 | NA | NA | SCC – NSCLC | III | 28 | 1 |
| 45 | F | 30–74 | No COPD | 0 | 8.5–9.9 | 5–5.9 | Ad-NSCLC | IV | 576 | 1 |
| 46 | F | 30–74 | Missing – spirometry | 1 | 4–8.4 | 5–5.9 | SCLC | IV | 130 | 1 |
| 47 | M | 30–74 | Known COPD | 1 | 4–8.4 | 5–5.9 | Ad-NSCLC | III | 38 | 1 |
| 48 | F | 75–91 | No COPD | 1 | 10–15 | 3–4.9 | Ad-NSCLC | IV | 44 | 1 |
| 49 | M | 30–74 | No COPD | 1 | 10–15 | 5–5.9 | Ad-NSCLC | I | 2,298 | 0 |
| 50 | M | 30–74 | No COPD | 0 | 10–15 | 6–10 | Ad-NSCLC | III | 132 | 1 |
| 51 | M | 30–74 | Undiagnosed COPD | 1 | 8.5–9.9 | 5–5.9 | Ad-NSCLC | III | 83 | 1 |
| 52 | M | 30–74 | No COPD | 1 | 10–15 | 3–4.9 | Ad-NSCLC | III | 204 | 1 |
| 53 | M | 30–74 | No COPD | 1 | 8.5–9.9 | 5–5.9 | SCLC | IV | 166 | 1 |
| 54 | F | 75–91 | Undiagnosed COPD | 0 | 8.5–9.9 | 6–10 | SCC – NSCLC | II | 50 | 1 |
| 55 | F | 30–74 | No COPD | 0 | 10–15 | 5–5.9 | SCLC | IV | 175 | 1 |
| 56 | M | 75–91 | No COPD | 1 | 8.5–9.9 | 3–4.9 | SCC – NSCLC | III | 28 | 1 |
| 57 | M | 30–74 | Undiagnosed COPD | 1 | 10–15 | 5–5.9 | SCC – NSCLC | I | 2,155 | 1 |
| 58 | M | 30–74 | Known COPD | 0 | 10–15 | 3–4.9 | Other – NSCLC | IV | 168 | 1 |
| 59 | F | 30–74 | Missing – spirometry | 0 | 4–8.4 | 3–4.9 | Ad-NSCLC | IV | 2 | 1 |
| 60 | M | 75–91 | Known COPD | 0 | 10–15 | 5–5.9 | SCC – NSCLC | III | 415 | 1 |
| 61 | M | 30–74 | No COPD | 0 | 10–15 | 5–5.9 | Ad-NSCLC | IV | 917 | 1 |
| 62 | M | 30–74 | Known COPD | 1 | 10–15 | 5–5.9 | SCC – NSCLC | III | 475 | 1 |
| 63 | F | 30–74 | No COPD | 0 | 8.5–9.9 | 5–5.9 | SCLC | IV | 1,485 | 1 |
| 64 | M | 30–74 | Known COPD | 1 | 4–8.4 | 3–4.9 | SCLC | III | 13 | 1 |
| 65 | M | 75–91 | Undiagnosed COPD | 1 | 8.5–9.9 | 3–4.9 | SCC – NSCLC | III | 460 | 1 |
| 66 | F | 30–74 | No COPD | 0 | NA | NA | Ad-NSCLC | III | 698 | 1 |
| 67 | M | 30–74 | Known COPD | 1 | 4–8.4 | 5–5.9 | Ad-NSCLC | IV | 226 | 1 |
| 68 | M | 30–74 | No COPD | 0 | 8.5–9.9 | 5–5.9 | Ad-NSCLC | IV | 184 | 1 |
| 69 | F | 30–74 | No COPD | 1 | 10–15 | 5–5.9 | Ad-NSCLC | I | 2,196 | 0 |
| 70 | F | 30–74 | No COPD | 0 | 10–15 | 5–5.9 | Ad-NSCLC | III | 265 | 1 |
| 71 | F | 30–74 | No COPD | 1 | 8.5–9.9 | 3–4.9 | SCC – NSCLC | II | 2,189 | 0 |
| 72 | M | 30–74 | No COPD | 1 | 10–15 | 3–4.9 | SCC – NSCLC | III | 287 | 1 |
| 73 | M | 30–74 | Known COPD | 1 | 8.5–9.9 | 5–5.9 | SCLC | IV | 492 | 1 |
| 74 | M | 30–74 | Missing – spirometry | 0 | 8.5–9.9 | 6–10 | SCC – NSCLC | IV | 501 | 1 |
| 75 | F | 30–74 | No COPD | 0 | 8.5–9.9 | 5–5.9 | Ad-NSCLC | II | 1,758 | 1 |
| 76 | M | 30–74 | No COPD | 0 | 10–15 | 5–5.9 | SCC – NSCLC | III | 432 | 1 |
| 77 | F | 30–74 | No COPD | 0 | 10–15 | 5–5.9 | SCLC | III | 2,142 | 0 |
| 78 | M | 30–74 | No COPD | 1 | NA | NA | SCC – NSCLC | II | 2,141 | 0 |
| 79 | M | 30–74 | No COPD | 1 | 8.5–9.9 | 3–4.9 | SCLC | IV | 18 | 1 |
| 80 | F | 30–74 | Missing – spirometry | 0 | 10–15 | 3–4.9 | SCLC | IV | 19 | 1 |
| 81 | M | 75–91 | Missing – spirometry | 0 | NA | NA | SCLC | IV | 35 | 1 |
| 82 | F | 30–74 | Missing – spirometry | 0 | 8.5–9.9 | 3–4.9 | SCC – NSCLC | IV | 135 | 1 |
| 83 | F | 30–74 | Known COPD | 1 | 4–8.4 | 3–4.9 | SCLC | IV | 111 | 1 |
| 84 | F | 30–74 | Known COPD | 0 | NA | NA | SCLC | IV | 58 | 1 |
| 85 | F | 30–74 | Undiagnosed COPD | 1 | 10–15 | 5–5.9 | SCC – NSCLC | III | 2,114 | 0 |
| 86 | F | 30–74 | No COPD | 0 | NA | NA | Ad-NSCLC | III | 254 | 1 |
| 87 | M | 75–91 | Missing – spirometry | 1 | NA | NA | SCLC | IV | 35 | 1 |
| 88 | F | 75–91 | No COPD | 0 | 4–8.4 | 3–4.9 | Ad-NSCLC | IV | 18 | 1 |
| 89 | M | 75–91 | Known COPD | 1 | 10–15 | 3–4.9 | SCLC | II | 417 | 1 |
| 90 | M | 30–74 | Known COPD | 1 | 10–15 | 5–5.9 | Ad-NSCLC | I | 249 | 1 |
| 91 | F | 30–74 | Known COPD | 1 | 4–8.4 | 6–10 | Ad-NSCLC | III | 630 | 1 |
| 92 | F | 30–74 | Undiagnosed COPD | 0 | 10–15 | 3–4.9 | Ad-NSCLC | IV | 22 | 1 |
| 93 | M | 30–74 | No COPD | 1 | 10–15 | 5–5.9 | Ad-NSCLC | III | 728 | 1 |
| 94 | M | 75–91 | No COPD | 1 | 8.5–9.9 | 3–4.9 | NA | III | 171 | 1 |
| 95 | F | 30–74 | Known COPD | 0 | 8.5–9.9 | 5–5.9 | SCLC | IV | 512 | 1 |
| 96 | F | 30–74 | Missing – spirometry | 1 | NA | NA | Ad-NSCLC | IV | 455 | 1 |
| 97 | M | 30–74 | Known COPD | 0 | 10–15 | 5–5.9 | SCLC | III | 441 | 1 |
| 98 | F | 75–91 | Known COPD | 1 | 4–8.4 | 5–5.9 | SCC – NSCLC | I | 1,329 | 1 |
| 99 | M | 75–91 | Known COPD | 1 | 4–8.4 | 3–4.9 | SCC – NSCLC | III | 163 | 1 |
| 100 | F | 30–74 | No COPD | 0 | 10–15 | 3–4.9 | SCLC | I | 1,902 | 0 |
| 101 | F | 75–91 | No COPD | 0 | 10–15 | 3–4.9 | Ad-NSCLC | IV | 537 | 1 |
| 102 | F | 75–91 | No COPD | 0 | 8.5–9.9 | 5–5.9 | NA | IV | 345 | 1 |
| 103 | F | 75–91 | Undiagnosed COPD | 0 | 4–8.4 | 5–5.9 | Ad-NSCLC | IV | 159 | 1 |
| 104 | M | 75–91 | Missing – spirometry | 0 | NA | NA | NA | IV | 14 | 1 |
| 105 | M | 30–74 | No COPD | 0 | 8.5–9.9 | 5–5.9 | SCLC | I | 1,983 | 0 |
| 106 | M | 75–91 | Known COPD | 1 | 8.5–9.9 | 5–5.9 | SCC – NSCLC | II | 526 | 1 |
| 107 | M | 30–74 | Missing – spirometry | 1 | NA | NA | Ad-NSCLC | IV | 222 | 1 |
| 108 | F | 75–91 | Known COPD | 1 | NA | NA | Ad-NSCLC | IV | 82 | 1 |
| 109 | M | 75–91 | Known COPD | 0 | 8.5–9.9 | 5–5.9 | Ad-NSCLC | IV | 168 | 1 |
| 110 | F | 75–91 | Known COPD | 1 | 4–8.4 | 5–5.9 | SCC – NSCLC | III | 197 | 1 |
| 111 | M | 30–74 | No COPD | 0 | NA | NA | Ad-NSCLC | IV | 1,412 | 1 |
| 112 | F | 30–74 | No COPD | 0 | 10–15 | 5–5.9 | SCC – NSCLC | IV | 1,092 | 1 |
| 113 | M | 75–91 | No COPD | 1 | 8.5–9.9 | 3–4.9 | SCC – NSCLC | II | 195 | 1 |
| 114 | M | 30–74 | Known COPD | 1 | 10–15 | 5–5.9 | SCLC | IV | 990 | 1 |
| 115 | F | 75–91 | No COPD | 1 | 10–15 | 5–5.9 | Ad-NSCLC | I | 1,254 | 1 |
| 116 | M | 30–74 | No COPD | 1 | 8.5–9.9 | 3–4.9 | SCC – NSCLC | III | 789 | 1 |
| 117 | F | 30–74 | Undiagnosed COPD | 1 | 10–15 | 5–5.9 | Ad-NSCLC | II | 1,892 | 0 |
| 118 | F | 75–91 | Known COPD | 1 | 8.5–9.9 | 3–4.9 | SCLC | I | 921 | 1 |
| 119 | F | 30–74 | Known COPD | 1 | 4–8.4 | 5–5.9 | SCC – NSCLC | III | 618 | 1 |
| 120 | M | 30–74 | Undiagnosed COPD | 0 | 10–15 | 5–5.9 | SCLC | I | 1,875 | 0 |
| 121 | F | 30–74 | Known COPD | 1 | 8.5–9.9 | 3–4.9 | SCC – NSCLC | III | 69 | 1 |
| 122 | M | 30–74 | Undiagnosed COPD | 1 | 4–8.4 | 3–4.9 | Ad-NSCLC | IV | 16 | 1 |
| 123 | F | 30–74 | No COPD | 1 | 10–15 | 3–4.9 | Ad-NSCLC | IV | 181 | 1 |
| 124 | M | 75–91 | Known COPD | 1 | 10–15 | 3–4.9 | SCC – NSCLC | IV | 81 | 1 |
| 125 | M | 30–74 | Known COPD | 1 | 10–15 | 3–4.9 | Ad-NSCLC | III | 195 | 1 |
| 126 | M | 30–74 | No COPD | 1 | 10–15 | 3–4.9 | SCC – NSCLC | III | 471 | 1 |
| 127 | F | 30–74 | Known COPD | 1 | 8.5–9.9 | 6–10 | SCC – NSCLC | III | 92 | 1 |
| 128 | M | 30–74 | No COPD | 1 | 8.5–9.9 | 3–4.9 | SCLC | IV | 3 | 1 |
| 129 | M | 30–74 | No COPD | 1 | 8.5–9.9 | 5–5.9 | SCC – NSCLC | IV | 153 | 1 |
| 130 | M | 30–74 | Known COPD | 1 | 10–15 | 6–10 | SCC – NSCLC | I | 555 | 1 |
| 131 | M | 30–74 | Known COPD | 1 | 10–15 | 3–4.9 | Ad-NSCLC | III | 148 | 1 |
| 132 | M | 75–91 | No COPD | 1 | NA | NA | Ad-NSCLC | I | 1,847 | 0 |
| 133 | M | 30–74 | Known COPD | 1 | 10–15 | 5–5.9 | SCC – NSCLC | III | 417 | 1 |
| 134 | M | 30–74 | No COPD | 1 | 10–15 | 5–5.9 | SCC – NSCLC | I | 1,840 | 0 |
| 135 | M | 30–74 | No COPD | 1 | 10–15 | 5–5.9 | SCC – NSCLC | II | 1,875 | 0 |
| 136 | F | 30–74 | No COPD | 1 | NA | NA | Ad-NSCLC | III | 776 | 1 |
| 137 | M | 30–74 | No COPD | 1 | 4–8.4 | 3–4.9 | Ad-NSCLC | IV | 14 | 1 |
| 138 | F | 30–74 | Undiagnosed COPD | 1 | 10–15 | 3–4.9 | SCLC | IV | 437 | 1 |
| 139 | F | 30–74 | Known COPD | 1 | 10–15 | 3–4.9 | Ad-NSCLC | III | 1,818 | 0 |
| 140 | M | 75–91 | No COPD | 1 | 8.5–9.9 | 5–5.9 | SCLC | III | 924 | 1 |
| 141 | M | 75–91 | Known COPD | 1 | 10–15 | 5–5.9 | SCC – NSCLC | I | 1,797 | 0 |
| 142 | M | 30–74 | Known COPD | 0 | 8.5–9.9 | 3–4.9 | SCC – NSCLC | IV | 214 | 1 |
| 143 | F | 30–74 | Known COPD | 1 | 8.5–9.9 | 5–5.9 | SCC – NSCLC | I | 1,744 | 0 |
| 144 | M | 75–91 | Missing – spirometry | 1 | 8.5–9.9 | 5–5.9 | SCC – NSCLC | III | 701 | 1 |
| 145 | M | 30–74 | No COPD | 0 | 10–15 | 3–4.9 | Ad-NSCLC | IV | 278 | 1 |
| 146 | M | 75–91 | Known COPD | 1 | 10–15 | 3–4.9 | Ad-NSCLC | IV | 397 | 1 |
| 147 | M | 30–74 | No COPD | 1 | 10–15 | 5–5.9 | SCLC | III | 176 | 1 |
| 148 | M | 30–74 | Missing – spirometry | 1 | 4–8.4 | 5–5.9 | Ad-NSCLC | IV | 37 | 1 |
| 149 | M | 30–74 | Known COPD | 0 | 10–15 | 5–5.9 | Ad-NSCLC | IV | 290 | 1 |
| 150 | F | 30–74 | Known COPD | 1 | 8.5–9.9 | 5–5.9 | NA | III | 249 | 1 |
| 151 | M | 30–74 | Missing – spirometry | 1 | NA | NA | Ad-NSCLC | IV | 131 | 1 |
| 152 | F | 30–74 | No COPD | 1 | NA | NA | SCLC | IV | 288 | 1 |
| 153 | M | 75–91 | Known COPD | 1 | 10–15 | 6–10 | SCC – NSCLC | I | 98 | 1 |
| 154 | F | 30–74 | No COPD | 0 | 10–15 | 5–5.9 | Ad-NSCLC | III | 1,747 | 0 |
| 155 | M | 30–74 | Known COPD | 1 | 8.5–9.9 | 5–5.9 | SCC – NSCLC | III | 741 | 1 |
| 156 | M | 75–91 | Missing – spirometry | 1 | NA | NA | SCLC | IV | 184 | 1 |
| 157 | F | 30–74 | No COPD | 1 | 8.5–9.9 | 5–5.9 | SCLC | IV | 398 | 1 |
| 158 | M | 30–74 | No COPD | 0 | 10–15 | 5–5.9 | SCLC | IV | 449 | 1 |
| 159 | M | 30–74 | No COPD | 0 | 10–15 | 3–4.9 | Ad-NSCLC | II | 1,437 | 1 |
| 160 | F | 30–74 | No COPD | 0 | 10–15 | 3–4.9 | Ad-NSCLC | IV | 166 | 1 |
| 161 | M | 30–74 | No COPD | 1 | 8.5–9.9 | 3–4.9 | Ad-NSCLC | IV | 141 | 1 |
| 162 | M | 30–74 | No COPD | 0 | 10–15 | 3–4.9 | SCC – NSCLC | III | 1,001 | 1 |
| 163 | F | 30–74 | Missing – spirometry | 1 | 10–15 | 5–5.9 | SCLC | IV | 181 | 1 |
| 164 | F | 75–91 | Known COPD | 1 | 10–15 | 5–5.9 | Ad-NSCLC | II | 335 | 1 |
| 165 | F | 30–74 | Missing – spirometry | 0 | NA | NA | SCC – NSCLC | IV | 236 | 1 |
| 166 | F | 75–91 | Known COPD | 1 | 8.5–9.9 | 5–5.9 | Other – NSCLC | IV | 68 | 1 |
| 167 | M | 30–74 | Known COPD | 1 | 8.5–9.9 | 6–10 | Ad-NSCLC | IV | 9 | 1 |
| 168 | M | 30–74 | Known COPD | 1 | 4–8.4 | 5–5.9 | SCLC | I | 445 | 1 |
| 169 | F | 30–74 | No COPD | 0 | NA | NA | SCLC | III | 514 | 1 |
| 170 | F | 30–74 | Known COPD | 0 | NA | NA | SCLC | IV | 333 | 1 |
| 171 | F | 30–74 | Known COPD | 1 | 10–15 | 3–4.9 | Ad-NSCLC | II | 243 | 1 |
| 172 | F | 30–74 | Known COPD | 1 | 4–8.4 | 5–5.9 | SCLC | IV | 244 | 1 |
| 173 | F | 30–74 | No COPD | 1 | 10–15 | 5–5.9 | SCC – NSCLC | III | 632 | 1 |
| 174 | M | 30–74 | Missing – spirometry | 1 | NA | NA | Ad-NSCLC | IV | 57 | 1 |
Notes: Time represents survival time (days) from diagnosis of primary lung cancer; D represents a censoring variable (1 if dead, 0 if alive at the end of the study period); PaO2 and PaCO2 in kPa. Patients with missing data were categorized as “missing – spirometry”.
Abbreviations: Ad-NSCLC, adenocarcinoma non-small-cell lung cancer; Emph, emphysema; F, female; M, male; NA, not available; PaO2, partial arterial oxygen pressure; SCC, squamous cell carcinoma; SCLC, small-cell lung cancer; PaCO2, partial arterial carbon dioxide pressure.